Developer docs
API playgroundTry for free, no card

Search company profiles

ObsEva

Full company profile

uuid0005bgo

Namestring
ObsEva
Websiteurl
obseva.com
Company typeenum
Public
Founded yearint
2012
Descriptiontext

ObsEva is a clinical-stage biopharmaceutical company focused on developing therapeutic treatments for women's reproductive medicine, with emphasis on endometriosis and related indications. Founded in 2012 and headquartered in Plan-les-Ouates (Geneva), Switzerland, the company is publicly traded on NASDAQ under the ticker OBSV and operates with a headcount of 11-50 employees. No specific named products, pipeline candidates, or therapeutic assets were disclosed in the available source material, and the company has not disclosed commercial revenue, customers, or distribution channels.

The company has historically funded its operations through multiple venture and debt financing rounds between 2013 and 2019, totaling approximately $228M, with investors including New Enterprise Associates, Sofinnova Partners, Novo Holdings, OrbiMed, and Oxford Finance LLC. The leadership team includes co-founders Ernest Loumaye (co-founder & CEO) and André Chollet (co-founder & CSO), alongside Elizabeth Garner MD MPH (Chief Medical Officer), Jean-Pierre Gotteland (Chief Scientific Officer and Head of R&D), Brandi Howard (CCO), and Luigi Marro (Chief Transformation Officer). Reported financials show a net loss of -$58.38M, consistent with pre-commercial clinical-stage burn. No AI/ML capabilities, technology platform details, patents, or marketing/distribution channels were disclosed in the source data.

Short descriptiontext

ObsEva is a clinical-stage biopharmaceutical company developing therapeutics for women's reproductive medicine, with focus on endometriosis, headquartered in Geneva, Switzerland and publicly traded on NASDAQ as OBSV.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPlan-les-ouates, Switzerland
HQ citystring
Plan-les-ouates
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
women's reproductive medicine, clinical-stage biopharmaceutical, endometriosis therapeutics, novel drug candidates, reproductive health treatments
Industry2 codes
1Reproductive Endocrinology & Infertility (IVF/Fertility)
CodeHLAKAJACPrimaryYes
2Sexual & Reproductive Health (STI Care, Vulvovaginal Disorders)
CodeHLAKAJAJPrimaryNo
Product category
Women's Health Pharmaceuticals
Social media profiles1 record
Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

ObsEva is a clinical-stage specialty biopharmaceutical company that discovers and develops novel therapeutics for women's reproductive medicine, with a primary focus on treatments for endometriosis and related indications. The company operates from Geneva, Switzerland, is publicly listed on NASDAQ (OBSV), and is pre-commercial, with no approved or revenue-generating products identified in the available source material.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

ObsEva is a clinical-stage biopharmaceutical company focused on developing treatments for women's reproductive health conditions. The company is based in Geneva, Switzerland, and trades on NASDAQ under the symbol OBSV. No specific named products, pipeline candidates, or therapeutic candidates were identified in the provided source material.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
1TherapeuticsMD
TypeDirect peer
Description

Women's health specialty pharmaceutical company focused on reproductive health and menopause-related therapies. Comparable in patient population, commercial model, and clinical-development profile.

2AbbVie
TypeBroad incumbent
Description

Global biopharma with Orilissa/Lupron for endometriosis and a major women's health franchise. Competes head-to-head with ObsEva in endometriosis and sets the commercial benchmark.

3Organon & Co.
TypeBroad incumbent
Description

Large women's-health-focused specialty pharma spun out of Merck, with a portfolio spanning fertility, contraception, and reproductive medicine. Comparable as a major incumbent in the same end markets ObsEva targets.

4Agile Therapeutics
TypeEmerging player
Description

Women's health specialty pharma focused on prescription contraceptives. Comparable in indication overlap (contraception/reproductive medicine) and small-cap clinical/commercial profile.

5Myovant Sciences (now Sumitomo Pharma)
TypeDirect peer
Description

Clinical-to-commercial biopharma historically focused on women's health and endocrine conditions, including endometriosis therapies (Myfembree/relugolix). Directly comparable in therapeutic focus, clinical-stage origin, and women's reproductive medicine pipeline.

6Gedeon Richter
TypeRegional player
Description

European-headquartered specialty pharma with a significant women's health and reproductive medicine portfolio. Comparable as a regional incumbent in the same therapeutic categories.

7Ferring Pharmaceuticals
TypeBroad incumbent
Description

Private specialty pharma with deep reproductive medicine and IVF portfolio (e.g., Menopur, Bravelle). Comparable as an incumbent in reproductive endocrinology and fertility treatments.

8Evofem Biosciences
TypeEmerging player
Description

Women's sexual and reproductive health company commercializing Phexxi for contraception and STI prevention. Comparable in therapeutic focus on reproductive medicine and similar small-cap commercial-stage profile.

9Daré Bioscience
TypeEmerging player
Description

Clinical-stage women's health biopharma developing novel therapies in contraception, reproductive health, and menopause. Comparable as a small-cap, clinical-stage women's reproductive health peer.

10Merck KGaA (Life Science / Healthcare)
TypeBroad incumbent
Description

Operates Gonal-f and other leading fertility treatments globally. Comparable as an established incumbent in the reproductive endocrinology and fertility space ObsEva targets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ObsEva

Women's Health Pharmaceuticalsobseva.com

ObsEva is a clinical-stage biopharmaceutical company developing therapeutics for women's reproductive medicine, with focus on endometriosis, headquartered in Geneva, Switzerland and publicly traded on NASDAQ as OBSV.

What ObsEva does

ObsEva is a clinical-stage biopharmaceutical company focused on developing therapeutic treatments for women's reproductive medicine, with emphasis on endometriosis and related indications. Founded in 2012 and headquartered in Plan-les-Ouates (Geneva), Switzerland, the company is publicly traded on NASDAQ under the ticker OBSV and operates with a headcount of 11-50 employees. No specific named products, pipeline candidates, or therapeutic assets were disclosed in the available source material, and the company has not disclosed commercial revenue, customers, or distribution channels.

The company has historically funded its operations through multiple venture and debt financing rounds between 2013 and 2019, totaling approximately $228M, with investors including New Enterprise Associates, Sofinnova Partners, Novo Holdings, OrbiMed, and Oxford Finance LLC. The leadership team includes co-founders Ernest Loumaye (co-founder & CEO) and André Chollet (co-founder & CSO), alongside Elizabeth Garner MD MPH (Chief Medical Officer), Jean-Pierre Gotteland (Chief Scientific Officer and Head of R&D), Brandi Howard (CCO), and Luigi Marro (Chief Transformation Officer). Reported financials show a net loss of -$58.38M, consistent with pre-commercial clinical-stage burn. No AI/ML capabilities, technology platform details, patents, or marketing/distribution channels were disclosed in the source data.

ObsEva firmographics

Firmographics
Name
ObsEva
Website
https://obseva.com
Company type
Public
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
ObsEva is a clinical-stage biopharmaceutical company developing therapeutics for women's reproductive medicine, with focus on endometriosis, headquartered in Geneva, Switzerland and publicly traded on NASDAQ as OBSV.
Ownership category
akta.pro rank

ObsEva industry classification

Industry
Product category
Women's Health Pharmaceuticals
akta.pro primary industry
Reproductive Endocrinology & Infertility (IVF/Fertility) (HLAKAJAC)
akta.pro secondary industry
Sexual & Reproductive Health (STI Care, Vulvovaginal Disorders) (HLAKAJAJ)

Keywords

  • Women's reproductive medicine
  • Clinical-stage biopharmaceutical
  • Endometriosis therapeutics
  • Novel drug candidates
  • Reproductive health treatments

Where ObsEva is headquartered

Location

Headquarters

HQ city
Plan-les-ouates
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

ObsEva business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

ObsEva product offering

Product offering

Core offering

ObsEva is a clinical-stage specialty biopharmaceutical company that discovers and develops novel therapeutics for women's reproductive medicine, with a primary focus on treatments for endometriosis and related indications. The company operates from Geneva, Switzerland, is publicly listed on NASDAQ (OBSV), and is pre-commercial, with no approved or revenue-generating products identified in the available source material.

Product overview

ObsEva is a clinical-stage biopharmaceutical company focused on developing treatments for women's reproductive health conditions. The company is based in Geneva, Switzerland, and trades on NASDAQ under the symbol OBSV. No specific named products, pipeline candidates, or therapeutic candidates were identified in the provided source material.

Differentiator

Problem solved

Functional benefit

Companies that use ObsEva

Customer profile

Segments1 record

Ideal customer profiles1 record

ObsEva technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

ObsEva partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves6 records

Expansion highlights3 records

ObsEva competitors and assessment

Company assessment

Direct peers

  • TherapeuticsMD: Women's health specialty pharmaceutical company focused on reproductive health and menopause-related therapies. Comparable in patient population, commercial model, and clinical-development profile.
  • Myovant Sciences (now Sumitomo Pharma): Clinical-to-commercial biopharma historically focused on women's health and endocrine conditions, including endometriosis therapies (Myfembree/relugolix). Directly comparable in therapeutic focus, clinical-stage origin, and women's reproductive medicine pipeline.

Broad incumbents

  • AbbVie: Global biopharma with Orilissa/Lupron for endometriosis and a major women's health franchise. Competes head-to-head with ObsEva in endometriosis and sets the commercial benchmark.
  • Organon & Co. Large women's-health-focused specialty pharma spun out of Merck, with a portfolio spanning fertility, contraception, and reproductive medicine. Comparable as a major incumbent in the same end markets ObsEva targets.
  • Ferring Pharmaceuticals: Private specialty pharma with deep reproductive medicine and IVF portfolio (e.g., Menopur, Bravelle). Comparable as an incumbent in reproductive endocrinology and fertility treatments.
  • Merck KGaA (Life Science / Healthcare): Operates Gonal-f and other leading fertility treatments globally. Comparable as an established incumbent in the reproductive endocrinology and fertility space ObsEva targets.

Emerging players

  • Agile Therapeutics: Women's health specialty pharma focused on prescription contraceptives. Comparable in indication overlap (contraception/reproductive medicine) and small-cap clinical/commercial profile.
  • Evofem Biosciences: Women's sexual and reproductive health company commercializing Phexxi for contraception and STI prevention. Comparable in therapeutic focus on reproductive medicine and similar small-cap commercial-stage profile.
  • Daré Bioscience: Clinical-stage women's health biopharma developing novel therapies in contraception, reproductive health, and menopause. Comparable as a small-cap, clinical-stage women's reproductive health peer.

Regional players

  • Gedeon Richter: European-headquartered specialty pharma with a significant women's health and reproductive medicine portfolio. Comparable as a regional incumbent in the same therapeutic categories.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

ObsEva social profiles

Digital presence

ObsEva financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ObsEva leadership team

Management profile

Number of profiles

Profiles8 records

ObsEva funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ObsEva M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ObsEva

What does ObsEva do?

ObsEva is a clinical-stage specialty biopharmaceutical company that discovers and develops novel therapeutics for women's reproductive medicine, with a primary focus on treatments for endometriosis and related indications. The company operates from Geneva, Switzerland, is publicly listed on NASDAQ (OBSV), and is pre-commercial, with no approved or revenue-generating products identified in the available source material.

Is ObsEva a public or private company?

ObsEva is a public company. It is classified as public and is currently operating.

When was ObsEva founded?

ObsEva was founded in 2012. It employs 11 to 50 people.

Where is ObsEva based?

ObsEva is headquartered in Plan-les-ouates, Switzerland, in the Europe region.

Who are ObsEva's main competitors?

Direct peers on record are TherapeuticsMD and Myovant Sciences (now Sumitomo Pharma). Broad incumbents are AbbVie, Organon & Co., Ferring Pharmaceuticals and Merck KGaA (Life Science / Healthcare). Emerging players are Agile Therapeutics, Evofem Biosciences and Daré Bioscience. Gedeon Richter is listed as a regional player.

Does ObsEva have an API?

No public API is recorded for ObsEva.

What industry is ObsEva in?

ObsEva's product category is Women's Health Pharmaceuticals. Its primary akta.pro industry code is HLAKAJAC, Reproductive Endocrinology & Infertility (IVF/Fertility), with a secondary code of HLAKAJAJ, Sexual & Reproductive Health (STI Care, Vulvovaginal Disorders).

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
European BiotechnologyCan biotech finally fix infertility?Biotech firms are developing drugs to improve IVF outcomes by targeting upstream biology, such as endometrial receptivity and male infertility. IVF success rates vary, with implantation failure affecting 10% of couples, and no approved treatment exists for male factor infertility. Companies like Igyxos and Oxolife are advancing therapies, but clinical endpoints remain unforgiving.Defense WorldObsEva (NASDAQ:OBSV) & Graybug Vision (NASDAQ:GRAY) Critical ReviewThis article presents a comparative financial analysis of two clinical-stage biopharmaceutical companies: ObsEva (NASDAQ:OBSV) and Graybug Vision (NASDAQ:GRAY), covering metrics including profitability, ownership, risk/volatility, and valuation. Graybug Vision outperforms ObsEva on 6 of 9 compared factors, including higher revenue ($426.96M vs. net loss), lower net loss (-$35.60M vs. -$58.38M), and more affordable valuation. Graybug Vision is a Redwood City, California-based company developing treatments for retinal diseases, while ObsEva is a Geneva, Switzerland-based company focused on women's reproductive health treatments.Defense WorldReviewing ObsEva (NASDAQ:OBSV) and Acerus Pharmaceuticals (OTCMKTS:TRLPF)This article presents a comparative financial analysis of ObsEva and Acerus Pharmaceuticals, two pharmaceutical companies, examining metrics including volatility, institutional ownership, earnings, and valuation. Acerus Pharmaceuticals shows higher revenue at $7.38 million versus ObsEva's negative earnings of $58.38 million, while trading at a lower price-to-earnings ratio indicating greater affordability. The analysis also includes profitability comparisons showing both companies with significant negative net margins, with Acerus at -254.66% and ObsEva at -416.36%.PR NewswireEndometriosis Treatment Market to Surge to US$ 3.1 Billion by 2034: Innovations in Surgical Procedures and Fertility-Preserving Medications Drive Market Growth | TMRTransparency Market Research projects the global endometriosis treatment market to grow from US$1.4 billion in 2023 to US$3.1 billion by 2034, representing a compound annual growth rate of 7.5%, driven by innovations in surgical procedures and fertility-preserving medications. Key regulatory milestones include the FDA's August 2022 approval of MYFEMBREE (developed by Myovant Sciences and Pfizer) for managing endometriosis-associated pain, and positive Phase 3 trial results for linzagolix announced by ObsEva SA in January 2022. Research efforts continue to focus on developing treatments that effectively manage symptoms without compromising fertility, with ongoing clinical trials and support from agencies such as the DBT/Wellcome India Alliance.GlobeNewswireObsEva Announces Application for a Moratorium to Facilitate Pivotal DealsObsEva SA's board sought a court moratorium in Geneva to protect negotiations for pivotal deals. The company aims to secure funding for operational expenditures until advanced business development discussions conclude. The moratorium would enable the company to focus on finalizing deals that could impact its trajectory.GlobeNewswireObsEva Files half Year 2023 Financial StatementsObsEva SA published its Half Year 2023 Financial Statements on September 27, 2023, pursuant to Art. 53 LR of the SIX Swiss Exchange. The company, a biopharmaceutical firm developing therapies for women's reproductive health, made the statements available on its website.GlobeNewswireAnnual General Meeting 2023ObsEva SA invited shareholders to its 2023 Annual General Meeting on June 29, 2023, in Geneva. The agenda includes approval of 2022 financials, a net loss of USD 36.37M, and board elections, including re-election of the CEO and a new board member.PR NewswireThinking about buying stock in Obseva SA, Rivian Automotive, Southwest Gas, Edible Garden, or Unicycive Therapeutics?On March 8, 2023, InvestorsObserver issued PriceWatch Alerts for five stocks: Obseva SA, Rivian Automotive, Southwest Gas, Edible Garden, and Unicycive Therapeutics. The alerts are based on a proprietary scoring system that evaluates both short-term and long-term factors to determine each stock's suitability for investment. InvestorsObserver provides investing tools aimed at both Wall Street firms and individual investors.PR NewswireThinking about buying stock in Mullen Automotive, Snap, Meta Platforms, Obseva SA, or Ambrx Biopharma?InvestorsObserver issued critical PriceWatch Alerts for the stocks of Mullen Automotive, Snap, Meta Platforms, Obseva SA, and Ambrx Biopharma on March 6, 2023. The alerts are based on a proprietary scoring methodology that evaluates short-term technical, long-term technical, and fundamental factors to determine investment suitability. InvestorsObserver provides these patented technology tools to Wall Street firms and self-directed investors.BenzingaObsEva, Ensysce Biosciences And 2 Other Stocks Under $1 Insiders Are Aggressively Buying - North AmericaThis Benzinga article reports on recent insider buying activity in penny stocks, noting the Dow Jones jumped 300+ points on Thursday. ObsEva SA Director Ernest Loumaye acquired 4 million shares at $0.11 per share for approximately $440,000, while the company announced a strategic reorganization to consolidate operations in Switzerland. The article also covers insider purchases at CLS Holdings USA (20,000 shares at $0.09) and BrightRock Gold Corp (52,466 shares at $0.15), with both stocks experiencing recent declines.